Mucosat ointment 5%, 30g

Degenerative-dystrophic diseases of the joints and spine:

osteoarthritis;

intervertebral osteochondrosis.

Outwardly. The ointment is applied in a thin layer on the skin over the lesion 2-3 times / day and rubbed for 2-3 minutes until completely absorbed.

The course of treatment is 2-3 weeks. If necessary, repeat the course of treatment.

Ointment for external use is homogeneous, light yellow in color with a specific odor of dimethyl sulfoxide.

1 g

chondroitin sodium sulfate (in terms of dry matter) 0.05 g

Excipients: dimethyl sulfoxide - 0.10 g, lanolin - 0.15 g, petroleum jelly - 0.5 g, purified water - up to 1.0 g.

• Hypersensitivity to the components of the drug;

• violation of the integrity of the skin in the places of the intended application of the drug.

  With care: pregnancy, breastfeeding period, age up to 18 years (efficacy and safety have not been established).

pharmachologic effect

MucosatЃ normalizes metabolism in hyaline tissue, stimulates regeneration (restorative) processes in articular cartilage, has analgesic and anti-inflammatory effects, slows down the progression of osteoarthritis and osteochondrosis. MucosatЃ contains chondroitin sulfate derived from cattle tissue. Chondroitin sulfate is a high molecular weight mucopolysaccharide, the most important component of cartilage and ligamentous apparatus. MucosatЃ has a chondroprotective and anti-inflammatory effect: stimulates the synthesis of proteoglycans and the regeneration of cartilage tissue; inhibits degeneration processes by inhibiting lysosomal enzymes, reducing the activity of superoxide radicals and inflammatory mediators; improves phosphorus-calcium metabolism.Dimethyl sulfoxide in the composition of MucosatЃ enhances the anti-inflammatory and analgesic effect. Possessing transporting properties, it increases the degree of absorption of the active substance. The inclusion of the drug in the combination therapy scheme contributes to a rapid decrease in swelling and soreness, an increase in joint mobility.

Pharmacokinetics

According to the data obtained in experimental studies on mice using radiolabeled 3H-chondroitin sulfate, the absorption rate of chondroitin sulfate is 14%. Chondroitin sulfate, after application to the skin, quickly and selectively enters the joint with the achievement of Cmax after 30 minutes and subsequent two-phase elimination of the drug from the cartilage tissue. The completion of the rapid phase of elimination occurs 1 hour after application. The retention time of the drug in the joint is 5 hours.

Side effect

Allergic reactions are possible.

Application during pregnancy and lactation

Due to the lack of data on the safety of the drug during pregnancy, the use of the drug during this period is possible only if the intended benefit to the mother outweighs the potential risk to the fetus. There are no clinical data on the use of the drug in women during breastfeeding.

Application in children

Do not use the drug without consulting a doctor in children under 18 years of age (efficacy and safety have not been established).

special instructions

Avoid getting the drug on mucous membranes and open wounds. Do not use the drug without consulting a doctor during pregnancy, during breastfeeding and in childhood. Influence on the ability to drive vehicles and use mechanisms

The drug does not affect the ability to drive vehicles, work with mechanisms and engage in other activities that require increased attention and speed of psychomotor reactions.

Overdose

There is no information on overdose.

Drug interactions

Cases of interaction or incompatibility with other drugs have not been described.